Clinical Risk Grouping Solution Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Clinical Risk Grouping Solution Market size was valued at USD 673.4 million in 2023 growing at a CAGR of 11.5% between 2024 and 2032. Clinical risk grouping solutions help in identifying high-risk patients and managing the care more efficiently. Therefore, one of the primary drivers is the increasing healthcare cost, as healthcare costs continue to rise, there is a greater need for solutions that can effectively manage and mitigate the expenses of treatment.
Additionally, the rise in prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer increases the need for effective population health management solutions. For instance, as per the report published by World Health Organization it has been reported that noncommunicable diseases (NCDs) kill 41 million people each year, equivalent to 74% of all deaths globally. Cardiovascular diseases account for most NCD deaths, or 17.9 million people annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million including kidney disease deaths caused by diabetes).
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Clinical Risk Grouping Solution Market size in 2023: | USD 673.4 million |
Forecast Period: | 2024 – 2032 |
Forecast Period 2023 - 2032 CAGR: | 11.5 |
2023 Value Projection: | USD 1.8 billion |
Historical Data for: | 2021 – 2023 |
No of Pages: | 128 |
Tables, Charts & Figures: | 213 |
Segments Covered: | Component, Application, End-use, and Region |
Growth Drivers: |
|
Pitfalls Challenges: |
|
Thus, the rapid increase in the prevalence of chronic disease globally is the major factor that is expanding the demand for clinical risk grouping solution for better risk stratification and to manage patient populations and improve healthcare outcomes, thereby driving the market growth. A clinical risk grouping solution (CRGS) is a sophisticated tool or system used in healthcare to categorize patients based on their clinical risk. The main purpose of CRGS is to predict and manage healthcare outcomes, optimize resource utilization, and improve patient care by identifying individuals at varying levels of health risk.
The increase in adoption of electronic health records (EHR) system at healthcare facilities such as hospitals, clinics, and ambulatory care centers, has been a key driver for clinical risk grouping solution industry. Also, innovations in data analytics, artificial intelligence, and machine learning enhance the capabilities of clinical risk grouping solutions such as EHRs software. These advancements enable more accurate risk prediction and better patient management.
Based on the component, the market is classified into software and services. The software segment dominated the market with revenue of USD 526.1 million in 2023.
Based on the application, the global clinical risk grouping solution market is classified into population health management, chronic disease management, clinical decision support, fraud detection and prevention, and other applications. The population health management segment dominated the market with market share of 33.2% in 2023.
Based on end-use, the clinical risk grouping solution market is classified into hospitals & clinics, ambulatory surgical centers, long term care centers, and other end-users. The hospitals & clinics segment is expected to exhibit 11.8% CAGR between 2024 - 2032.
In 2023, North America secured a substantial market share of 45.2% in the global clinical risk grouping solution market and is expected to dominate throughout the forecast period.
Germany to experience the highest growth rate in the Europe market.
The Asia Pacific clinical risk grouping solution market is expected to grow with a significant CAGR of 11.9% during the forecast period.
The clinical risk grouping solution industry is characterized by intense competition among key players aiming to expand their market presence. Leading companies are focusing on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market position. These efforts are aimed at enhancing their service offerings, expanding their geographic reach, and investing in advanced technologies. The market also witnesses the entry of new players, intensifying the competitive landscape further.
Prominent players operating in the clinical risk grouping solution industry are as mentioned below:
Market, By Component
Market, By Application
Market, By End-use
The above information is provided for the following regions and countries:
North America clinical risk grouping solution industry accounted for 45.2% market share in 2023 and is projected to witness substantial gains from 2024 to 2032, led by the presence of strong technological structure with continuous innovation in healthcare.
The population health management segment in the clinical risk grouping solution industry accumulated 33.2% market share in 2023 and is estimated to depict substantial growth between 2024 and 2032, due to the growing prevalence of chronic diseases.
The software component segment in the clinical risk grouping solution industry accounted for USD 526.1 million in 2023 due to its ability to be customized according to the specific needs of different healthcare providers.
Clinical risk grouping solution industry size was worth USD 673.4 million in 2023 and is projected to expand at 11.5% CAGR from 2024 to 2032, owing to the rise in prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer.